Form 6-K ASTRAZENECA PLC For: Nov 19
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of��November 2014
Commission File Number:��001-11960
AstraZeneca PLC
2 Kingdom Street, London W2 6BD
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X �����������Form 40-F��__
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): �����������
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes��__�����������������No X
If Yes is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):���82-_____________
�
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
AstraZeneca launches and prices a �750,000,000 7 year bond issue
AstraZeneca PLC, rated A2 (stable outlook) by Moody's and AA- (negative outlook) by Standard & Poor's, announces today the successful pricing of euro medium term notes in an aggregate principal amount of �750,000,000 maturing on 24 November 2021 with a coupon of 0.875% (the "Notes").
The proceeds of the issue will be used to fund the repayment of outstanding euro medium term notes in an aggregate principal amount of �750,000,000 maturing in January 2015.
The Notes are being issued under the U.S.$5,000,000,000 Euro Medium Term Note Programme of AstraZeneca PLC.
The Notes will be issued to institutional investors outside the US in accordance with Regulation S of the U.S. Securities Act of 1933, as amended. The Notes will be admitted to listing on the UK Listing Authority's Official List and to trading on the London Stock Exchange's regulated market.
Notes to editors
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.
�
�
�
�
�
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AstraZeneca PLC
Date:�19 November�2014
|
By:��/s/ Adrian Kemp
|
� |
Name: Adrian Kemp
|
� |
Title: Company Secretary
|
�
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- AstraZeneca (AZN) Tops Q1 EPS by 110c; reaffirms guidance
- Deep Ellum Art Company Announces Electrifying Lineup Of Creeds And Desert Hearts To Ignite Dallas's Music Scene
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!